Biotech investing is not limited by access to information.It is limited by the ability to make consistently better decisions in a highly uncertain environment. Even deep diligence and strong science often fail to translate into consistent outcomes. This led us to shift away from picking individual winners and toward understanding how experienced biotech investors allocate capital. One pattern stood out: Companies held across multiple top biotech…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.